Lazard Capital Downgrades Transcept Pharmaceuticals (TSPT) to Hold
Tweet
Share
E-mailGet Alerts TSPT Hot Sheet
Price: $1.70 --0%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Lazard Capital downgraded Transcept Pharmaceuticals (NASDAQ: TSPT) from Buy to Hold.
For more ratings news on Transcept Pharmaceuticals click here and for the rating history of Transcept Pharmaceuticals click here.
Shares of Transcept Pharmaceuticals closed at $4.87 yesterday.
For more ratings news on Transcept Pharmaceuticals click here and for the rating history of Transcept Pharmaceuticals click here.
Shares of Transcept Pharmaceuticals closed at $4.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Downgrades Legend Biotech Corp. (LEGN) to Perform, 'CEO/Partnership/Competition Overhangs to Cap Upside'
- China Merchants Securities Downgrades Tencent Music Entertainment Group (TME) to Hold
- LifeSci Capital Downgrades Liquidia Technologies (LQDA) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
